https://www.nejm.org/doi/full/10.1056/NEJMp2034334

On the Shoulders of Giants — From Jenner’s Cowpox to mRNA Covid Vaccines

In September 2008, Katalin Karikó, Drew Weissman, and their colleagues at the University of Pennsylvania modified messenger RNA (mRNA) using nucleoside analogues. These modifications stabilized the molecule and eliminated its capacity for inducing innate immunity, thereby making mRNA a promising tool for both gene replacement and vaccination.¹ In December 2020, on the basis of safety and efficacy data generated in two large, placebo-controlled studies, the Food and Drug Administration (FDA) issued emergency use authorizations for two mRNA vaccines for the prevention of Covid-19. Clearance of this hurdle by the first mRNA vaccines represents the most recent in a series of breakthroughs in the realm of viral vaccines, each building on the last and each with a compelling record of disease prevention.

Factbox-Latest on the worldwide spread of the coronavirus The World Trade Organization said risks from the uneven roll-out of coronavirus vaccination campaigns and the possible emergence of vaccine-resistant strains clouded the outlook for the global trade in goods, while raising its growth forecast slightly. Reuters Staff U.S.

...

* All health workers in Italy must have coronavirus jabs, the government said, in a potentially controversial move aimed at protecting vulnerable patients and pushing back against ‘no-vax’ sentiment.

An estimated 10% to 30% of people who get COVID-19 suffer from lingering symptoms of the disease, or what's known as "long COVID."

Judy Dodd, who lives in New York City, is one of them. She spent nearly a year plagued by headaches, shortness of breath, extreme fatigue and problems with smell, among other symptoms.

She says she worried that this "slog through life" was going to be her new normal.

Everything changed after she got her COVID-19 vaccine.

"I was like a new person, it was the craziest thing ever," says Dodd, referring to how many of her health problems subsided significantly after her second shot.

More consumers will soon be able to test themselves for COVID-19 from the comfort of their own home. On Wednesday, the Food and Drug Administration approved two rapid antigen home tests for use in the U.S.

Americans will soon be able to purchase Abbott's BinaxNOW and Quidel Quickvue tests at drug stores. The two options join a test made by Ellume, which received FDA approval in December, in the market. The two, newly-approved swab tests will be sold at a lower price point.

The BinaxNOW and Quickvue tests are expected to be sold in two-packs for around $15-20; Ellume costs $30.